Sandoz Wants Novo's Prandin Patent Ruled Invalid Again
Generic-drug maker Sandoz Inc. filed a suit Wednesday in Michigan federal court seeking to have Novo Nordisk Inc.'s patent protecting the diabetes drug Prandin declared — for a second time —...To view the full article, register now.
Already a subscriber? Click here to view full article